Latest From Alaric DeArment
The RNA drug’s accelerated approval brings Sarepta’s exon-skipping market share to nearly 30%.
With elderly patients disproportionately facing hospitalization and death from COVID-19, success in the clinic would create an important market for the drug.
Deal Snapshot: Sentynl will pay $20m in upfront and regulatory milestone payments through FDA approval, while Cyprium will retain 100% ownership of the priority review voucher.
Tirzepatide’s efficacy seems to outweigh tolerability concerns at the lower doses, but the highest dose may be relegated to niche use.
The agreement focuses on respiratory viruses, especially influenza, and includes a $225m upfront payment plus an increase in GSK’s equity investment in Vir.